We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chromosome Buffers Improve Understanding of Melanoma

By LabMedica International staff writers
Posted on 01 Oct 2014
Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma, the deadliest form of skin cancer.

The ends of chromosomes are protected from instability by tandem nucleotide repeats, known as telomeres and these telomeres shorten both with age and following exposures associated with cancer risk, such as smoking and ultraviolet (UV) irradiation.

An international team of scientists led by those at the University of Leeds (UK) investigated variants identified by the telomere meta-analysis in a genome-wide association study (GWAS) of melanoma. More...
The study consisted of 11,108 case patients and 13,933 control patients from Europe, Israel, the USA, and Australia. The scientists concentrated on seven single nucleotide polymorphisms (SNPs) from the telomere meta-analysis.

In phase 1, samples were genotyped on the HumanHap300 BeadChip version 2 duo array with 317k tagging SNPs (Illumina; San Diego, CA, USA) and in France, cases were genotyped on the Illumina HumanCNV370k array. The phase 2 samples were genotyped on the Illumina 610k array.

The team created a score representing genetically-determined telomere length based on all the established telomere associated genes and found that this score was associated with melanoma risk. The one in four people predicted to have the longest telomeres are at 30% increased risk of developing melanoma compared to those one in four predicted to have the shortest telomeres.

Mark M. Iles, PhD, the led author of the study said, “For the first time, we have established that the genes controlling the length of these telomeres play a part in the risk of developing melanoma. More studies are needed to better understand the relationship between melanoma and telomeres, but learning more about how an individual's genetic telomere profile influences their risk developing melanoma may help us. It will improve our understanding of melanoma biology and gives us a target towards developing potential treatments as well as potentially helping shape advice on what behavioral changes people might make.” The study was published in the October 2014 issue of the Journal of the National Cancer Institute.

Related Links:
.
University of Leeds 
Illumina 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.